Tag
This study identifies immune biomarkers, including proliferative CD8+ T cells, CD68+ macrophages, and PD-1 expression, which differentiate high-risk oral tongue epithelial dysplasia and may improve patient risk stratification beyond convent
Anti-PD-1 antibody exacerbates pressure overload-induced heart failure by promoting CXCR3+ CD8+ T cell infiltration, which impairs cardiomyocyte mitochondrial function via granzyme B and perforin. This study identifies a novel immunopathoge
Immune checkpoint therapy has become a major advance in pediatric Hodgkin lymphoma and is now being actively tested across selected pediatric non-Hodgkin lymphomas with strong PD-L1 biology.
A phase 2 arm of the EDGE‑Gastric trial reports a 59% confirmed objective response rate and median PFS 12.9 months with domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX in untreated HER2‑negative advanced gastric
In a phase 2 cohort (EDGE‑Gastric A1), domvanalimab (anti‑TIGIT) plus zimberelimab (anti‑PD‑1) combined with FOLFOX produced a 59% ORR, median PFS 12.9 months and median OS 26.7 months in 41 previously untreated HER2‑negative gastroesophage
AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune
